These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24036042)

  • 21. Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
    Zang J; Liang X; Huang Y; Jia Y; Li X; Xu W; Chou CJ; Zhang Y
    J Med Chem; 2018 Jun; 61(12):5304-5322. PubMed ID: 29787262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors.
    Kuo GH; Wang A; Emanuel S; Deangelis A; Zhang R; Connolly PJ; Murray WV; Gruninger RH; Sechler J; Fuentes-Pesquera A; Johnson D; Middleton SA; Jolliffe L; Chen X
    J Med Chem; 2005 Mar; 48(6):1886-900. PubMed ID: 15771433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs).
    Wang X; Chen Z; Tong L; Tan S; Zhou W; Peng T; Han K; Ding J; Xie H; Xu Y
    Eur J Med Chem; 2013 Jul; 65():477-86. PubMed ID: 23770449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B.
    Collins I; Caldwell J; Fonseca T; Donald A; Bavetsias V; Hunter LJ; Garrett MD; Rowlands MG; Aherne GW; Davies TG; Berdini V; Woodhead SJ; Davis D; Seavers LC; Wyatt PG; Workman P; McDonald E
    Bioorg Med Chem; 2006 Feb; 14(4):1255-73. PubMed ID: 16249095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
    Wurz RP; Liu L; Yang K; Nishimura N; Bo Y; Pettus LH; Caenepeel S; Freeman DJ; McCarter JD; Mullady EL; Miguel TS; Wang L; Zhang N; Andrews KL; Whittington DA; Jiang J; Subramanian R; Hughes PE; Norman MH
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5714-20. PubMed ID: 22832322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Magnolol suppresses vascular endothelial growth factor-induced angiogenesis by inhibiting Ras-dependent mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways.
    Kim KM; Kim NS; Kim J; Park JS; Yi JM; Lee J; Bang OS
    Nutr Cancer; 2013; 65(8):1245-53. PubMed ID: 24066970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of spirocyclic sulfonamides as potent Akt inhibitors with exquisite selectivity against PKA.
    Xu R; Banka A; Blake JF; Mitchell IS; Wallace EM; Bencsik JR; Kallan NC; Spencer KL; Gloor SL; Martinson M; Risom T; Gross SD; Morales TH; Wu WI; Vigers GP; Brandhuber BJ; Skelton NJ
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2335-40. PubMed ID: 21420856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
    Salerno S; Marini AM; Fornaciari G; Simorini F; La Motta C; Taliani S; Sartini S; Da Settimo F; García-Argáez AN; Gia O; Cosconati S; Novellino E; D'Ocon P; Fioravanti A; Orlandi P; Bocci G; Dalla Via L
    Eur J Med Chem; 2015 Oct; 103():29-43. PubMed ID: 26318056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The anti-angiogenic and anti-tumor activity of synthetic phenylpropenone derivatives is mediated through the inhibition of receptor tyrosine kinases.
    Lee JS; Kang Y; Kim JT; Thapa D; Lee ES; Kim JA
    Eur J Pharmacol; 2012 Feb; 677(1-3):22-30. PubMed ID: 22200628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diallyl trisulfide inhibits angiogenic features of human umbilical vein endothelial cells by causing Akt inactivation and down-regulation of VEGF and VEGF-R2.
    Xiao D; Li M; Herman-Antosiewicz A; Antosiewicz J; Xiao H; Lew KL; Zeng Y; Marynowski SW; Singh SV
    Nutr Cancer; 2006; 55(1):94-107. PubMed ID: 16965246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brucine, an indole alkaloid from Strychnos nux-vomica attenuates VEGF-induced angiogenesis via inhibiting VEGFR2 signaling pathway in vitro and in vivo.
    Saraswati S; Agrawal SS
    Cancer Lett; 2013 May; 332(1):83-93. PubMed ID: 23348691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of new 4-alkoxyquinazoline-based derivatives as potent VEGFR2 inhibitors.
    Yin Y; Sha S; Wang YT; Wu X; Wang SF; Qiao F; Lv PC; Zhu HL
    Chem Biol Drug Des; 2015 Nov; 86(5):1323-9. PubMed ID: 26032487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents.
    Abadi AH; Abou-Seri SM; Abdel-Rahman DE; Klein C; Lozach O; Meijer L
    Eur J Med Chem; 2006 Mar; 41(3):296-305. PubMed ID: 16494969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and biological evaluation of novel oxazolo[5,4-d]pyrimidines as potent VEGFR-2 inhibitors.
    Deng YH; Xu D; Su YX; Cheng YJ; Yang YL; Wang XY; Zhang J; You QD; Sun LP
    Chem Biodivers; 2015 Apr; 12(4):528-37. PubMed ID: 25879498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors.
    Machado VA; Peixoto D; Costa R; Froufe HJ; Calhelha RC; Abreu RM; Ferreira IC; Soares R; Queiroz MJ
    Bioorg Med Chem; 2015 Oct; 23(19):6497-509. PubMed ID: 26344591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of novel vascular endothelial growth factor receptor 2 inhibitors: a virtual screening approach.
    Zhang L; Wang X; Feng J; Jia Y; Xu F; Xu W
    Chem Biol Drug Des; 2012 Dec; 80(6):893-901. PubMed ID: 22913881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A development of chimeric VEGFR2 TK inhibitor based on two ligand conformers from PDB: 1Y6A complex--medicinal chemistry consequences of a TKs analysis.
    Lintnerová L; García-Caballero M; Gregáň F; Melicherčík M; Quesada AR; Dobiaš J; Lác J; Sališová M; Boháč A
    Eur J Med Chem; 2014 Jan; 72():146-59. PubMed ID: 24368209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity.
    Elsayed NMY; Serya RAT; Tolba MF; Ahmed M; Barakat K; Abou El Ella DA; Abouzid KAM
    Bioorg Chem; 2019 Feb; 82():340-359. PubMed ID: 30428414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and evaluation of 8-amino-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives as glycogen synthase kinase-3 (GSK-3) inhibitors.
    Chun K; Park JS; Lee HC; Kim YH; Ye IH; Kim KJ; Ku IW; Noh MY; Cho GW; Kim H; Kim SH; Kim J
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3983-7. PubMed ID: 23683591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
    Chen MC; Lee CF; Huang WH; Chou TC
    Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.